Skip to news

PANXEON Blood Test Moves Pancreatic Cancer Screening Closer

A 1,785-person study reports a promising blood test for early pancreatic cancer, but prospective screening trials will determine whether it changes care.

By THE COLDAI TIMES desk (AI-assisted)Editor: Shayan SalehiPublished 3 min read502 words

Key facts

  • PANXEON was studied in 1,785 people across four countries and achieved 86.8% sensitivity for stage I–II pancreatic cancer when combined with CA19-9.[1]
  • The assay showed potential for detecting high-grade dysplasia in people with high-risk pancreatic cysts.[1][2]
  • The test remains investigational and requires larger prospective validation before routine clinical use.[1][2]
  • Ajay Goel disclosed a paid consulting relationship with Biocartis, which has an option to acquire PANXEON rights.[2]

A new investigational blood test has reported encouraging results for detecting pancreatic ductal adenocarcinoma before the disease reaches advanced stages, potentially addressing one of oncology’s most difficult diagnostic problems. The test, called PANXEON, combines a microRNA signature with the established tumor marker carbohydrate antigen 19-9, or CA19-9. Its results were published September 16, 2026, in *Nature Medicine* after an international study involving 1,785 participants from four countries. [1]

What changed

In the study’s testing cohort, the combined assay detected stage I and II pancreatic cancer with 86.8% sensitivity. The researchers reported false-positive rates of 3.2% among lower-risk controls and 15.6% among people at higher risk. The test also showed potential for identifying high-grade dysplasia in pancreatic cysts, a precancerous condition that can sometimes precede invasive cancer. [1]

PANXEON is designed to read several biological signals rather than rely on a single marker. It measures circulating and exosomal microRNAs—small molecules involved in regulating gene activity—and integrates them with CA19-9. That multi-marker approach is intended to improve performance over CA19-9 alone, which can be elevated for reasons unrelated to pancreatic cancer and is not accurate enough for general-population screening.

The study also tracked a small group of patients during treatment. MicroRNA levels fell during neoadjuvant chemotherapy and after surgery, then rose before recurrence in some cases. That finding raises the possibility that the assay could eventually help monitor disease as well as detect it, although the evidence is too limited to establish a clinical monitoring role.

Why it matters

Pancreatic cancer is frequently diagnosed after it has spread, when surgery is less likely to be curative. Earlier detection could expand the number of patients eligible for surgery and other potentially definitive treatments. A blood-based test would also be easier to repeat than imaging or invasive tissue sampling, particularly for people with pancreatic cysts, inherited risk, or chronic pancreatitis.

The significance is therefore not that PANXEON is ready for routine use. It is that the study offers evidence that a liquid biopsy can distinguish early pancreatic cancer from controls across multiple countries and risk groups. Independent coverage emphasized that the test’s value may come from evaluating higher-risk patients rather than attempting to screen the entire population, where low disease prevalence can make even a relatively specific test produce many false alarms. [2]

What remains uncertain

The study was observational, and its results do not yet show that using PANXEON reduces pancreatic-cancer deaths. The high false-positive rate in the high-risk cohort could lead to repeat imaging, biopsies, anxiety, and unnecessary procedures. The researchers say larger prospective studies are needed, particularly trials that follow at-risk people over time and measure whether the test detects cancers earlier in real clinical practice.

There is also a potential commercial conflict: researcher Ajay Goel is a paid consultant to Biocartis, which holds an option to acquire rights to PANXEON. That disclosure does not invalidate the findings, but it reinforces the need for independent validation before adoption. For now, PANXEON is a promising diagnostic candidate—not a proven screening standard.

Add The ColdAI Times as a preferred source on Google

Related stories